Abstract
Summary
We studied the effectiveness of teriparatide (TPTD) for treating medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and examined differences in the clinical outcomes following daily versus weekly TPTD. The outcomes were significantly improved in the entire patient series and the daily group.
Purpose
Teriparatide (TPTD) treatment for Stage II–III medication-related osteonecrosis of the jaw (MRONJ) in osteoporotic patients has yielded promising results in uncontrolled studies. The daily administration and the weekly administration of TPTD have been reported to improve outcomes in MRONJ. Herein, we sought to identify differences in the clinical outcomes of MRONJ patients treated with daily TPTD versus weekly TPTD.
Methods
We enrolled 13 patients and randomly assigned them to receive either of two treatments: 1×/week 56.5-μg TPTD injection for 6 months (weekly group; n = 6 patients after 1 dropout), or 20-μg TPTD injection daily for 6 months (daily group; n = 6 patients). Patients in both groups received conventional therapy plus intensive antibiotic therapy as necessary. We compared the changes in the patients’ clinical stage of MRONJ, bone metabolism, percentage of bone formation, and bone turnover markers between the weekly and daily groups.
Results
TPTD treatment with MRONJ led to partial remission or complete remission in 5 daily-group patients and 3 weekly-group patients. The MRONJ stage was significantly improved from baseline to 6 months of treatment in the entire series of 12 patients (p = 0.008); the weekly group did not show significant improvement, but the daily group did (p = 0.01).
Conclusions
This study provides the first comparison of clinical outcomes between MRONJ patients who received daily or weekly TPTD injections. Six months of treatment with TPTD realized a significant improvement of MRONJ stage in both the entire patient series and the daily group.
Similar content being viewed by others
References
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72:1938–1956
Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347
Matsui A, Kurihara J, Morishima H, Suzuki H, Sato S, Yamauchi K, Takahashi T (2015) Medication related osteonecrosis of the jaw (MRONJ): a retrospective survey of a series of patients treated according to the AAOMS guidelines. J Oral Maxillofac Surg Med Pathol 27:757–763
Oswald AJ, Berg J, Milne G, Ralston SH (2014) Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice. Calcif Tissue Int 94:176–182
Walsh JB, Lems WF, Karras D, Langdahl BL, Ljunggren O, Fahrleitner-Pammer A, Barrett A, Rajzbaum G, Jakob F, Marin F (2012) Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 90:373–383
Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–2474
Lau AN, Adachi JD (2009) Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol 36:1835–1837
Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y (2013) Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 115:e31–e37
Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573–580
Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, Taskesen F (2013) The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg 42:1475–1480
Ersan N, van Ruijven LJ, Bronckers AL, Olgac V, Ilguy D, Everts V (2014) Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol 43:20130144
Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T (2016) Treatment responses with once-weekly teriparatide therapy for osteoporosis. Osteoporos Int 7(10):3057–3062
Sugie-Oya A, Takakura A, Takao-Kawabata R, Sano H, Shimazu Y, Isogai Y, Yamaguchi A, Ishizuya T (2016) Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions. J Bone Miner Metab 34:303–314
Yamachika E, Matsubara M, Ikeda A, Matsumura T, Moritani N, Iida S (2015) Treatment of osteonecrosis of the jaw. J Craniofac Surg 26:e575–e577
Yoshiga D, Yamashita Y, Nakamichi I, Tanaka T, Yamauchi K, Yamamoto N, Nogami S, Kaneuji T, Mitsugi S, Sakurai T, Kiyomiya H, Tominaga K, Morimoto Y, Takahashi T (2013) Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 24:2365–2369
Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502
Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106
Yamamoto T, Hasegawa T, Sasaki M, Hongo H, Tsuboi K, Shimizu T, Ota M, Haraguchi M, Takahata M, Oda K, Luiz de Freitas PH, Takakura A, Takao-Kawabata R, Isogai Y, Amizuka N (2016) Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice. Endocrinology 157:2604–2620
Assaf AT, Zrnc TA, Remus CC, Adam G, Zustin J, Heiland M, Friedrich RE, Derlin T (2015) Intraindividual comparison of preoperative (99 m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw. J Craniomaxillofac Surg 43:1461–1469
Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB (2011) Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med 36:17–20
Ohbayashi Y, Nakai F, Iwasaki A, Ogawa T, Yamamoto Y, Nishiyama Y, Miyake M (2017) The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. Odontology 105:382–390
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443
Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:CD001347
Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860
Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, Kiyoki M (1998) Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int 63:143–147
Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW (1998) Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 13:1721–1729
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478–1487
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley L, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom 20:8–24
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916
Esen E, Lee SY, Wice BM, Long F (2015) PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling. J Bone Miner Res 30:1959–1968
Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632–3638
Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, Baek WY, Kim JE, Kronenberg HM (2012) Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 27:2075–2084
Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259–50272
Keskinruzgar A, Bozdag Z, Aras MH, Demir T, Yolcu U, Cetiner S (2016) Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg 74:68–78
Zandi M, Dehghan A, Mohammadi-Mofrad A, Amini P, Vahdatinia F (2017) Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats. J Craniomaxillofac Surg 45:275–280
Kuroshima S, Entezami P, McCauley LK, Yamashita J (2014) Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing. Osteoporos Int 25:1141–1150
Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, Kuroshima S, Kawakami A, Asahina I (2015) Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg 44:1558–1564
Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY (2012) Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 23:2721–2725
Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH (2014) Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int 25:1625–1632
Tsuchie H, Miyakoshi N, Iba K, Kasukawa Y, Nozaka K, Dohke T, Kosukegawa I, Aizawa T, Maekawa S, Abe H, Takeshima M, Tomite T, Segawa T, Ouchi K, Kinoshita H, Suzuki M, Yamashita T, Shimada Y (2018) The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: Comparison between daily and weekly administration. Osteoporos Int 29(12):2659–2665. https://doi.org/10.1007/s00198-018-4658-7
Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A (1997) Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961–2970
Yamane H, Takakura A, Shimadzu Y, Kodama T, Lee JW, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Acute development of cortical porosity and endosteal naive bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12:e0175329
Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, Fuereder T, Willinger B, Sulzbacher I, Steininger C (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 6:31604
Valour F, Senechal A, Dupieux C et al (2014) Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist 7:183–197
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Ethics statement
The study protocol, patient information, and informed consent forms were approved by the Kagawa University Institutional Review Board (approval #2012CS020).
Statement of informed consent
Informed consent was obtained from all of the patients.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ohbayashi, Y., Iwasaki, A., Nakai, F. et al. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporos Int 31, 577–585 (2020). https://doi.org/10.1007/s00198-019-05199-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-05199-w